Search Results

Your search for Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP,Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP / September 10, 2022

Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma

“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning!” —Steve Jobs Relapsed and refractory multiple myeloma remains a treatment challenge. Promising responses have been demonstrated with bispecific antibodies, with a...

multiple myeloma

immunotherapy

By Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP / November 25, 2021 / 2021 ASCO Annual Meeting

High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy

“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s extensive coverage of the 2021 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel treatments under study in high-risk multiple myeloma. For...

Nov

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP,Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP matches 2 pages

Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma

High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC